By Colin Kellaher Shares of BioVie Inc. rose sharply in premarket trading Tuesday after the clinical-stage biopharmaceutical company reported positive results from a pair of Phase 2 studies assessing the
Biogen Inc. shares BIIB, -0.43% rose 4.7% in premarket trade Monday, after MorphoSys and partner Roche said a trial of a treatment for Alzheimer’s disease failed to meet its main Read more Roche Holding AG said Monday that Phase 3 Graduate studies of gantenerumab, for treatment of early Alzheimer’s disease, failed to meet its primary endpoints. The Swiss pharma company ROG, -3.72% Read more A couple of years ago I bought a big book of crosswords and started doing one every day. I found something peculiar. With each crossword, I would initially get stuck Read more Where is the hysteria? Where is the mass panic? Where is the preening virtue signaling? Why aren’t people on Twitter showing off by screaming “granny killer!” at anyone who disagrees Read more There may not be a “magic pill,” but there are ways to stave off dementia and improve your brain health, one scientist says. Crossword puzzles and Sudoku are helpful in Read more Biogen Inc. BIIB, -1.93% and Eisai Co. Ltd. 4523, +3.57% are getting closer to a possible approval of their new treatment for Alzheimer’s disease, with plans to submit the drug Read more The things to remember about dementia are that it is absolutely horrible for you and everyone around you; it’s a high probability; and when it comes to fighting it or Read more An experimental Alzheimer’s disease treatment developed by Eisai and Biogen that appears to slow cognitive decline sent shares in both companies soaring, but some analysts are tempering their expectations until Read more Next stop regulatory approval. That was the view of analysts at Mizuho Securities, who late Tuesday lifted shares of Biogen Inc. BIIB, +1.04% to buy from neutral after the pharmaceutical Read more
Biogen shares jump 4.7% premarket on hopes for its Alzheimer’s treatment lecanemab
Roche says Phase 3 studies for Alzheimer’s drug failed to meet primary endpoints
Want to slow, delay or reverse dementia? Try this classic game.
When will we care as much about Alzheimer’s as we did about COVID-19?
4 things you can do to fight dementia and improve your memory
Biogen and Eisai make plans to take another Alzheimer’s drug to the FDA
People who do this one thing have HALF the Alzheimer’s risk
Getting Medicare to cover Eisai and Biogen’s promising new Alzheimer’s therapy is ‘another bridge to cross’
Regulatory approval is next: Mizuho lifts Biogen to buy on news of Alzheimer’s drug success
